JANUS HENDERSON GROUP PLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.

Quarter-by-quarter ownership
JANUS HENDERSON GROUP PLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$25,014,496
-35.3%
480,273
-21.4%
0.02%
-33.3%
Q2 2023$38,676,860
-7.8%
610,915
-21.1%
0.02%
-14.3%
Q1 2023$41,936,959
+176.5%
774,540
+170.2%
0.03%
+154.5%
Q4 2022$15,167,289
+43.8%
286,689
-36.8%
0.01%
+37.5%
Q3 2022$10,550,540
-1.7%
453,482
+141.1%
0.01%
+14.3%
Q2 2022$10,731,000
+38.1%
188,051
+48.1%
0.01%
+75.0%
Q1 2022$7,772,000
+0.5%
127,001
-14.1%
0.00%
+33.3%
Q4 2021$7,730,000
+42.0%
147,866
+1.2%
0.00%
+50.0%
Q3 2021$5,445,000
+1.0%
146,165
+10.7%
0.00%0.0%
Q2 2021$5,391,000
+35.3%
132,085
+12.7%
0.00%0.0%
Q1 2021$3,984,000
+167.6%
117,223
+150.6%
0.00%
+100.0%
Q4 2020$1,489,000
+169.7%
46,783
+33.7%
0.00%
Q3 2017$552,000
+26.9%
35,0000.0%0.00%
Q2 2017$435,00035,0000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders